Squarepoint’s Genocea Biosciences, Inc. GNCA Stock Holding History

Squarepoint’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-25,966	Closed	-$59K	–	3454
2020 Q3	$59K	Sell	25,966 -106,582	-80%	-$280K	﹤0.01%	2352
2020 Q2	$305K	Buy	132,548 +118,087	+817%	+$272K	﹤0.01%	1597
2020 Q1	$25K	Buy	14,461 +1,639	+13%	+$3.31K	﹤0.01%	1770
2019 Q4	$27K	Buy	+12,822	New	+$30.4K	﹤0.01%	2417
2019 Q3	–	Sell	-39,427	Closed	-$155K	–	2879
2019 Q2	$155K	Buy	39,427 +38,176	+3,052%	+$199K	﹤0.01%	2159
2019 Q1	$6K	Sell	1,251 -2,551	-67%	-$12.6K	﹤0.01%	2098
2018 Q4	$9K	Buy	3,802 +355	+10%	+$1.77K	﹤0.01%	1888
2018 Q3	$21K	Buy	+3,447	New	+$18.2K	﹤0.01%	1941
2016 Q3	–	Sell	-5,363	Closed	-$176K	–	1392
2016 Q2	$176K	Buy	+5,363	New	+$197K	0.01%	916

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's GNCA Position: Q4 2020 in Review

Squarepoint sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2020, closing a stake of 25,966 shares — an estimated $59K sold.

Squarepoint first reported a position in GNCA in Q2 2016 and held it in 9 quarters. The position peaked at $305K in Q2 2020. 39 funds tracked by Wall St. Rank hold GNCA as of Q4 2020.

Squarepoint reported no remaining Genocea Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
Squarepoint sold 25,966 Genocea Biosciences, Inc. shares in Q4 2020, an estimated $59K.
Squarepoint first reported a position in Genocea Biosciences, Inc. in Q2 2016 and held it in 9 quarters.
Squarepoint's Genocea Biosciences, Inc. position peaked at $305K in Q2 2020.
39 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2020.

Based on Squarepoint's 13F filing for Q4 2020, filed 16 Feb 2021.